Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera in adolescents with somatostatin receptor-positive GEP-NETs and exploratory PPGL
NL-OMON50857Phase 2Withdrawn
- Sponsor
- Advanced Accelerator Applications
- Start
- Jun 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, pheochromocytoma and Paraganglioma (PGL), sponsored by Advanced Accelerator Applications. Primary endpoints: Target organ absorbed radiation doses and Adverse events and laboratory toxicities after first administration. Planned start Jun 2021; status: withdrawn.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid TumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NL-OMON50857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50857.